Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field and providing high-quality educational and networking opportunities for oncology professionals.

Biosyngen, an innovative biotechnology company specializing in immune cell therapies, has showcased its groundbreaking technology on gene-modified, functionally enhanced tumor-infiltrating lymphocytes (TILs) derived from liver cancer biopsy samples.

BioSyngen has secured ten clinical trial approvals in China and the U.S. for its innovative fourth-generation oncology therapies. Currently, our leading pipeline product, BRG01, is in the pivotal Phase II clinical trial stage for solid tumors. Additionally, the first patients have been enrolled in the Phase I trials for our other groundbreaking therapies, BST02 and BRL03, with completion of Phase I trials anticipated later this year.

Abstract Title

Pre-clinical Development of Genetically Modified Tumor-infiltrating Lymphocytes using Biopsy Samples from Liver Cancer Patients

Abstract No.

1034P

Tumor-infiltrating lymphocytes (TILs) are heterogeneous lymphocyte populations within the tumor microenvironment that contains T cells capable of recognizing tumor- or virus-associated antigens. In February of this year, the FDA approved the first TIL-based therapy used with IL-2 for advanced metastatic/recurrent melanoma. However, due to the variability in T cell infiltration between hot and cold tumors, differential abundance of antigen-specific T cells with robust immune response functionality, and the dependence of TIL anti-tumor efficacy on concomitant use of high-dose IL-2 combination therapy, the therapeutic applications of non-edited TILs are quite limited outside of melanoma.

To address these challenges, Biosyngen has developed a proprietary platform for expanding TILs from biopsy samples, achieving production of 10¹¹ cells within four weeks. Additionally, the company has established a stable gene modification platform that reprograms TIL metabolism, enhances TIL activity and sustained antitumor efficacy by expressing membrane anchor proteins. Anti-tumor efficacy has significantly enhanced (without IL-2 co-injection) and no obvious toxicity observed.

Biosyngen houses best-in-class proprietary TIL platform aiming to expand the clinical applications of TIL technology with following features:

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

RIYADH, Saudi Arabia, Oct. 5, 2024 /PRNewswire/ --The Literature, Publishing & Translation Commission, part of the Saudi Ministry of Culture, has revealed that the Riyadh Book Fair 2024 is its largest edition yet, featuring a diverse range of translated international books. With more than 2,000 local, Arab, and international publishers participating, the Fair has strengthened its position as a leading cultural event in the Arab world. This year's edition promotes Saudi Arabia's cultural openness and supports the spread of cross-border knowledge.

The 2024 Fair edition stands out for hosting renowned thinkers, intellectuals, and global figures in literature, art, and knowledge who share their insights and success stories with the public. Among the key speakers are Fareed Zakaria, acclaimed media personality and author; Walter Isaacson, world-renowned biographer; poet and writer Kwame Alexander; and acclaimed novelist Jonathan Franzen. The Fair also features prominent literary and artistic figures from the Middle East.

Dr Mohammed Hasan Alwan, CEO of the Literature, Publishing & Translation Commission, emphasised the significance of the Fair, stating: "The Riyadh International Book Fair is not only one of the most important book fairs in the Arab region but also a premier platform for publishers and authors to expand their reach in the Arab cultural market. This year's edition is especially notable for its focus on cultural diversity and translation, with an exceptional programme featuring some of the world's leading intellectuals."

During his visit, His Excellency Chang Hua, the Chinese Ambassador to Saudi Arabia, expressed admiration for the Saudi public's enthusiasm for reading. CNN's Fareed Zakaria praised the Kingdom's remarkable transformation and its growing global influence.

This year also marks the return of the popular "Riyadh Reads French" initiative, featuring several French publishers. Al-Saeed Ezz, Communication Officer at the French Embassy, noted that this year's programme has expanded to include children's activities and free French language courses in collaboration with the French Cultural Institute, bringing French culture closer to Saudi visitors.

The Riyadh International Book Fair plays a key role in supporting Saudi Vision 2030's cultural goals, contributing to the Kingdom's cultural economy, projected to reach $9.3 billion. Attracting over one million visitors annually, it ranks among the highest-selling book fairs in the Arab world.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Riyadh International Book Fair 2024: Expanding Global Dialogue through the Largest Collection of Translated Works